If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
== Dimer alkaloids == In addition to the described above monomeric alkaloids, there are also dimeric, and even trimeric and tetrameric alkaloids formed upon condensation of two, three, and four monomeric alkaloids. Dimeric alkaloids are usually formed from monomers of the same type through the following mechanisms:
== Early life == Simco was born on January 29, 1982, in Houston, Texas, to Anita Isaacs, a maid, and Ronald Simco, a Vietnam War veteran with severe post-traumatic stress disorder, who worked various jobs, including as a police officer and Walmart manager. His mother grew up in Shaker Heights, Ohio, descending from a family of German Jews and Lithuanian Jews that included several survivors and victims of the Holocaust. Riff Raff is the second of four siblings. He and his family lived in Copperfield, a suburb 25 miles northwest of Houston. Growing up he was obsessed with basketball, playing frequently with other children in his neighborhood. The Simcos had moved to nearby Stone Creek. He attended Langham Creek High School, where he was shooting guard on his school's basketball team, before dropping out in his senior year. Shortly thereafter he obtained his GED. After his parents divorced, his father was diagnosed with tonsil cancer and the family moved to Duluth, Minnesota, to get his father out of the heat into a cooler environment. For a time, Riff Raff and his siblings were shuttled back and forth between Duluth and Houston, where their mother remained. In 2001, he enrolled at Hibbing Community College in Hibbing, Minnesota, where he played on the basketball team for a month and majored in liberal arts. Feeling out of place, he dropped out in 2003 and moved back to Houston, where he painted cars in the in-vogue "candy-colored" style and gradually built his new identity. He eventually relocated to Los Angeles and began to take his rapping career seriously.
Consequently, the Royal College of General Practitioners and the Royal College of Physicians ended their corporate partnerships as it would be in breach of their ethical guidance. The Novo UK General Manager, Pinder Sahota, chose to resign as President of the ABPI prior to the suspension. In August 2023, one of the first lawsuits was filed alleging that Novo's Ozempic and Eli Lilly's Mounjaro (tirzepatide) caused severe gastrointestinal side effects, including gastroparesis. The lawsuit was brought on behalf of Jaclyn Bjorklund, a Louisiana woman represented by Morgan & Morgan, who alleged that she suffered persistent vomiting and other serious injuries after using the drugs and that the manufacturers failed to adequately warn patients and physicians about the risks. In September 2023, the law firm Motley Rice filed a lawsuit on behalf of a Pennsylvania woman who had been taking weight-loss drug Wegovy. The lawsuit alleges that the plaintiff experienced severe stomach cramping, vomiting, and nausea requiring hospitalization, and that Novo failed to adequately warn patients about the risk of gastroparesis. In February 2024, the United States Judicial Panel on Multidistrict Litigation ordered that 55 lawsuits pending in federal courts be consolidated into a multidistrict litigation. The majority of the cases were against Novo, but some were brought against Eli Lilly. As of August 2024 there were 235 active Ozempic lawsuits.
This is a list of topics related to HIV/AIDS, a spectrum of conditions caused by human immunodeficiency virus (HIV) infection. Many of the topics listed here were originally taken from the public domain U.S. Department of Health Glossary of HIV/AIDS-Related Terms, 4th Edition.
=== Dosage forms === Lidocaine, usually in the form of its hydrochloride salt, is available in various forms including many topical formulations and solutions for injection or infusion. It is also available as a transdermal patch, which is applied directly to the skin.
Sources: en.wikipedia.org
In 1953, a reader letter to the Philadelphia Bulletin reported that Italian-Americans working at the World War I–era shipyard known as Hog Island, where emergency shipping was produced for the war effort, introduced the sandwich by putting various meats, cheeses, and lettuce between two slices of bread. This became known as the "Hog Island" sandwich; shortened to "Hoggies", then the "hoagie". Dictionary.com offers the following origin of the term hoagie - n. American English (originally Philadelphia) word for "hero, large sandwich made from a long, split roll"; originally hoggie (c. 1936), traditionally said to be named for the jazz musician Hoagy Carmichael (1899–1981), but the use of the word predates his celebrity and the original spelling seems to suggest another source (perhaps "hog"). The modern spelling dates from about 1945; it may have been altered by influence of Carmichael's nickname. The Philadelphia Almanac and Citizen's Manual offers a different explanation saying the sandwich was created by early-twentieth-century street vendors called "hokey-pokey men", who sold antipasto salad, meats, cookies, and buns with a cut in them. When Gilbert and Sullivan's operetta H.M.S. Pinafore opened in Philadelphia in 1879, bakeries produced a long loaf called the pinafore. Entrepreneurial "hokey-pokey men" sliced the loaf in half, stuffed it with antipasto salad, and sold the world's first "hoagie". This hypothesis seems unlikely, as "hokey pokey" men were known street vendors of an ice cream product.
Vacuum deaerator Composite plastic moulding processes; Production of most types of electric lamps, vacuum tubes, and CRTs where the device is either left evacuated or re-filled with a specific gas or gas mixture; Semiconductor processing, notably ion implantation, dry etch and PVD, ALD, PECVD and CVD deposition and so on in photolithography; Electron microscopy; Medical processes that require suction; Uranium enrichment; Medical applications such as radiotherapy, radiosurgery and radiopharmacy; Analytical instrumentation to analyse gas, liquid, solid, surface and bio materials; Mass spectrometers to create a high vacuum between the ion source and the detector; Vacuum coating on glass, metal and plastics for decoration, for durability and for energy saving, such as low-emissivity glass, hard coating for engine components (as in Formula One), ophthalmic coating, milking machines and other equipment in dairy sheds; Vacuum impregnation of porous products such as wood or electric motor windings; Air conditioning service (removing all contaminants from the system before charging with refrigerant); Trash compactor; Vacuum engineering; Sewage systems (see EN1091:1997 standards); Freeze drying; and Fusion research. In the field of oil regeneration and re-refining, vacuum pumps create a low vacuum for oil dehydration and a high vacuum for oil purification. A vacuum may be used to power, or provide assistance to mechanical devices. In hybrid and diesel engine motor vehicles, a pump fitted on the engine (usually on the camshaft) is used to produce a vacuum.
== Epidemiology == Acanthosis nigricans is reported worldwide, with prevalence varying by age, ethnicity and underlying metabolic risk. In clinic- and community-based samples of people with obesity and insulin resistance, reported prevalence ranges from about 7% to over 70%, depending on the population and diagnostic criteria used. Higher rates are consistently observed among individuals of African, Hispanic/Latino, Native American and some Asian ancestries, reflecting both genetic susceptibility and a higher burden of obesity and metabolic syndrome in many of these populations. In children and adolescents, the prevalence of acanthosis nigricans has risen alongside increasing rates of overweight and obesity and is common in pediatric cohorts with insulin resistance or metabolic syndrome. Across studies, acanthosis nigricans is more frequent among people with higher body mass index, increased waist circumference and biochemical markers of insulin resistance.
This suggests BDNF is not only capable of initiating synapse formation through its effects on NMDA receptor activity, but it can also support the regular every-day signaling necessary for stable memory function. BDNF is also required for stabilizing actin polymerization in spines through triggering the activation of the WAVE regulatory complex.
=== Other Latin American and Caribbean === Prime Minister of Trinidad and Tobago Kamla Persad-Bissessar praised the US attack and encouraged more operations against drug traffickers, saying: "The pain and suffering the cartels have inflicted on our nation is immense. I have no sympathy for traffickers; the US military should kill them all violently." Raising concerns that the bodies washing ashore won't be investigated, and placing Trinidad and Tobago at odds with other CARICOM members, she supports the strikes, saying: "I much prefer seeing drug and gun traffickers blown to pieces than seeing hundreds of our citizens murdered each year because of drug-fueled gang violence." The family of one of the Trinidad missing said due process was not given and accused Trump of "killing poor people". Colombian president Gustavo Petro said that attacking the boat occupants in drug interdictions rather than capturing them amounted to murder. On 11 November, Petro announced he would suspend sharing of intelligence with the US while strikes on vessels continued; Efecto Cocuyo reported that Colombian Ministers of Defense and of the Interior stated on 13 November that Colombia would continue cooperating with the US. When asked whose side he was on, Brazilian president Luiz Inácio Lula da Silva said he was on the side of peace, favored negotiations, and that US forces in the Caribbean had become a source of tension.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.